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Parkinson’s disease (PD) is a neurologic move-
ment disorder in which neurons of the substan-
tia nigra, which are responsible for dopamine
production, attenuate in number or become
functionally impaired. Resultant symptoms
include resting tremor in the extremities and
head, limb and/or trunk rigidity, bradykinesia,
and postural instability. Although the primary
cause of the destruction or failure of substantia
nigra cells is unknown, mounting evidence
exists for both environmental and genetic
determinants. A growing body of evidence
suggests that heavy metal cations stimulate free
radical formation in the brain and can lead to
neurodegeneration via peroxidative damage to
the cell membrane (Sandhir et al. 1994).
Increasing levels of heavy metal cations stimu-
late the conformational changes that can lead
to ﬁbrillation of recombinant α-synuclein. The
aggregation and ﬁllibration of α-synuclein pro-
voked by the presence of heavy metal cations
could directly cause the intracellular protein
inclusions that are observed in the substantia
nigra of PD patients (Uversky et al. 2001).
Results from several epidemiologic studies fur-
ther support an association between PD and
exposure to heavy metals (Aquilonius and
Hartvig 1986; Rybicki et al. 1993; Tanner
et al. 1989). Our previous results demonstrated
a 2-fold increase in the risk of PD among
workers with > 20 years of occupational expo-
sure to Pb. Associations of such chronic occu-
pational exposure to combinations of Pb–iron
and Pb–copper were even more robust (Gorell
et al. 1997).
Although several studies have examined
the relationship between blood Pb levels and
environmental Pb exposure, results from blood
Pb analysis are not noteworthy. Research into
long-term or distant past Pb exposures is con-
founded by the body’s ability to purge metals
quickly from the blood stream. Because the
half-life of Pb in blood is approximately
1 month, blood Pb levels only reveal if the
individual has experienced a relatively current
exposure to environmental Pb. Thus, blood Pb
levels indicate only acute and recent exposures
to Pb rather than representing a chronic
and/or extended exposure history. Rather than
within circulating blood, the main repository
for chronic Pb stores in the body is within
bone (Hu et al. 1998). Pb is stored in the bone
by replacing calcium of the hydroxy-apatite
crystals of the bone mineral. Through a con-
tinual process of bone remodeling, synthesis,
and reabsorption, Pb is released into the blood
stream and circulates throughout the body. In
the brain, Pb diffuses easily across the blood
brain barrier and binds to sulphydryl groups,
resulting in Pb neurotoxicity that leads the
neurodegeneration via intracellular oxidative
damage (Bradbury and Deane 1993; Popenoe
and Schmaeler 1979; Quinlan et al. 1988;
Rossman 2006; Sandhir et al. 1994).
Additionally, while the half-life of Pb in
blood is very short, the half-life of Pb in bone
is measured in years and decades, depending
on the type of bone [the hard bone of the
tibia (half-life of approximately 20 years)
releases Pb more slowly over time than the
soft, spongy bone of the calcaneus (half-life of
≤ 10 years)] and the individual’s metabolic
rate of leaching and clearance (Patterson
1980). Measuring Pb concentration in bone
using K-shell X-ray ﬂuorescence (K-XRF) pro-
vides a proxy for current whole-body Pb con-
tent, independent of whether the exposure is
current (Hu et al. 1991; Todd and Chettle
1994). Because K-XRF measurements esti-
mate the current level of blood stores in the
body, they can be used to construct an indi-
rect assessment of an individual’s past expo-
sures to Pb. If the exposure to Pb was
experienced at some time in the past, the indi-
vidual’s body will have cleared some amount
of Pb between the last period of exposure and
the time of the K-XRF measurement. This
clearance rate of Pb from bone is predictable
and can be used in a physiologically based
pharmacokinetic (PBPK) model to estimate
the level of Pb in the body at the actual time
of the exposure. Kinetic modeling allows for a
more complete picture of the individual’s life-
time occupational Pb exposure by combining
current body stores, as detected by bone Pb
levels; current exposures, as indicated by blood
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BACKGROUND: Several epidemiologic studies have suggested an association between Parkinson’s
disease (PD) and exposure to heavy metals using subjective exposure measurements. 
OBJECTIVES: We investigated the association between objective chronic occupational lead exposure
and the risk of PD. 
METHODS: We enrolled 121 PD patients and 414 age-, sex-, and race-, frequency-matched controls in
a case–control study. As an indicator of chronic Pb exposure, we measured concentrations of tibial
and calcaneal bone Pb stores using 109Cadmium excited K-series X-ray ﬂuorescence. As an indicator of
recent exposure, we measured blood Pb concentration. We collected occupational data on participants
from 18 years of age until the age at enrollment, and an industrial hygienist determined the duration
and intensity of environmental Pb exposure. We employed physiologically based pharmacokinetic
modeling to combine these data, and we estimated whole-body lifetime Pb exposures for each indi-
vidual. Logistic regression analysis produced estimates of PD risk by quartile of lifetime Pb exposure. 
RESULTS: Risk of PD was elevated by > 2-fold [odds ratio = 2.27 (95% confidence interval,
1.13–4.55); p = 0.021] for individuals in the highest quartile for lifetime lead exposure relative to
the lowest quartile, adjusting for age, sex, race, smoking history, and coffee and alcohol consump-
tion. The associated risk of PD for the second and third quartiles were elevated but not statistically
signiﬁcant at the α = 0.05 level. 
CONCLUSIONS: These results provide an objective measure of chronic Pb exposure and conﬁrm our
earlier ﬁndings that occupational exposure to Pb is a risk factor for PD.
KEY WORDS: case control, chronic toxicity, K-X-ray ﬂuorescence, lead exposure, neurodegeneration,
occupational exposure, Parkinson’s disease. Environ Health Perspect 114:1872–1876 (2006).
doi:10.1289/ehp.9102 available via http://dx.doi.org/ [Online 18 August 2006]Pb levels; and both current and past environ-
mental exposures, as reported by the individ-
ual and qualified by industrial hygienist
assessment to assess the timing and intensity of
the exposure (Leggett 1993).
In this study, we further evaluated the risk
of PD in response to the total body Pb bur-
den. To accomplish this, we conducted a
case–control study with the following objec-
tives: a) to integrate historical exposure infor-
mation with current measurements of cortical
and trabecular bone Pb obtained by current
K-XRF and blood Pb; b) to reconstruct the
Pb exposure history using PBPK models; and
c) to use the resultant estimate of the net body
Pb burden over time (dose) to calculate a
quantitative relationship between the lifetime
exposure and the risk of PD.
Materials and Methods
Setting and study population. Study partici-
pants were patients who had received their pri-
mary health care services between 1995 and
1999 from the Henry Ford Health System
(HFHS), the second largest health care
provider in southeastern Michigan. We identi-
ﬁed potential study participants ≥ 50 years of
age from a database containing data for
127,742 patients using the internal Corporate
Data Store (CDS) computerized billing system
within HFHS (Figure 1). We implemented a
multistep screening process for the ascertain-
ment of PD diagnosis. First, we used the
International Classification of Disease, Ninth
Revision (ICD-9; World Health Organization
1978) codes 332 and 332.0 to identify poten-
tial cases from the CDS; we identiﬁed a total of
2,678 potential cases. In the second step of
screening, we reviewed electronic and/or hard
copies of medical records of the 2,678 individ-
uals for a diagnosis of idiopathic PD within the
previous 5 years. Of these, a total of 249 indi-
viduals had confirmed clinical diagnoses of
PD. We randomly identiﬁed potential controls
from the CDS and frequency-matched them
on sex, race, and age at the time diagnosis of
PD (± 5 years). Frequency-matching reduces
the primary effects of these variables in the
analysis phase. We reviewed the medical
records of potential cases to exclude patients
with secondary Parkinsonism, stroke-induced
Parkinsonism, and Parkinsonism as a result of
head injury, brain tumor, encephalitis, neuro-
leptic use, carbon monoxide intoxication,
Huntington’s disease, Wilson’s disease, essen-
tial or intention tremor, dementia, verbal
aphasia, seizure disorder, psychosis or depres-
sion, substance abuse; we also excluded
patients with hydrocephalus. One of the inves-
tigators (J.G.) and two registered nurses in the
Department of Neurology reviewed all of the
medical records and made the ﬁnal screening
eligibility judgment.
We mailed a recruitment packet contain-
ing a letter explaining the purpose of the
study, a one-page sheet of frequently asked
questions about PD and the research study,
and a brochure describing the procedure of
bone Pb measurement using K-XRF to a total
of 249 cases and 1,519 potential control
volunteers. A week after mailing, trained inter-
viewers made follow-up telephone calls and
invited the potential participants to participate
in the study. Those individuals who agreed to
do so underwent a telephone-administered
shortened version of the Mini Mental State
Exam (MMSE; Roccaforte et al. 1992) as the
ﬁnal step in the screening process. A total of
228 eligible cases and 1,334 eligible controls
were asked to participate in the study; 121
cases (53.1%) and 414 controls (31.0%)
agreed and were enrolled in the study.
Participants were scheduled for a clinic visit
during which they were administered the full
version of the MMSE and the K-XRF proce-
dure, had blood drawn for laboratory analysis
of Pb, and were interviewed for potential occu-
pational exposure to Pb and for other possible
risk factors for PD. To rule out patients with
dementia, all final participants had a full
MMSE score ≥ 24 (American Psychiatric
Association 1994; Anthony et al. 1982;
Folstein et al. 1975). Participants gave written
informed consent and were minimally com-
pensated, and the study was approved by the
institutional review board within the HFHS.
Pb exposure assessment. During a face-to-
face interview using a modiﬁed version of the
Pb exposure questionnaire instrument of
Kosnett et al. (1994), study participants
described the types and duration of occupa-
tions held throughout their adult life (age 18 to
present). One of the investigators (G.K.), an
industrial hygienist, blinded to the status of the
study participant, ranked the probability of Pb
exposure and the intensity of exposure as high,
medium, or low for each occupation lasting
longer than 6 months. High-probability expo-
sures occurred when the activity performance
exceeded 90% of the work period and involved
direct handling of Pb-containing materials, or
the liberation of Pb-containing fumes, dusts, or
liquids in the vicinity of the subject. Moderate
probabilities of Pb exposure (10–90% of the
time) and low probabilities (< 10% of the
time) were associated with “occasional” (mod-
erate) or “rare or never” (low) contact with
leaded materials or Pb-containing fumes,
dusts, or liquids. The intensity of exposure
was rated high if the probability of exposure
was also high and the permissible exposure
level (PEL) standard (Occupational Safety and
Health Administration 1998) was exceeded
> 50% of the time, giving a high score using
the paradigm of Sharp et al. (1991). Moderate
intensities of exposure were associated with
10–10% of the PEL and a moderate level by
Sharp et al. (1991), and low intensities were
< 10% of the PEL with a low exposure score,
according to Sharp et al. (1991). We then
combined probability and intensity scores with
duration for each occupation, so each subject
had a cumulative Pb exposure history over
time from age 18 to the time of recruitment.
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Figure 1. Diagram of case and control selection, recruitment, and enrollment.
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into studyBone Pb measurement by K-XRF. We per-
formed K-XRF measurement of bone Pb on
each subject during 40 min of exposure to the
left tibia and calcaneus to a sealed 1.1 GBq
(30 mCi) 109Cd source, placed in a commercial
detector (Canberra Industries, Meriden, CT),
2 cm from each measured bone. The reﬂected
88 keV γ-rays were amplified and digitized,
and we collected the energy spectrum on a
multichannel analyzer. We determined the
amplitudes of α1 and β1 K-series X rays and
their ratios to the amplitude of the coherent
scatter peak for each human bone spectrum
and evaluated calibration lines generated from
a set of 10 standard Pb-doped plaster-of-Paris
phantoms with Pb concentrations ranging
from 0 to 200 µg/g. Using a nonlinear chi-
square minimization procedure, we ﬁt models
of the spectral features to each individual’s
data (Bevington 1969; Marquardt 1963). The
amplitudes of the Pb X rays and of the coher-
ently scattered 88 keV γ-rays were extracted
for further analysis. We based quantity assess-
ment on independent estimates of the ampli-
tudes of α1 and β1 K-band X rays and their
ratios to the amplitude of the coherent scatter
peak, giving two calibration lines correspond-
ing to α and β X rays. The same two ratios
were determined for each human bone spec-
trum and evaluated against the appropriate
calibration lines, making due allowance for
the difference in coherent scattering between
bone and plaster of Paris. We calculated the
result for an individual subject as the inverse
variance of the weighted mean of the two
ratios. At the time of K-XRF measurement,
we drew 5 mL venous blood from each sub-
ject for determination of blood Pb levels.
Samples were analyzed by atomic absorption
spectroscopy at Henry Ford Hospital
(Detroit, MI) (Miller et al. 1987).
PBPK modeling of lifetime Pb exposure.
We integrated Pb exposure duration and
intensity data with current measures of blood
and skeletal Pb concentrations using the
International Commission for Radiation
Protection (ICRP) PBPK model (Leggett
1993). We developed an algorithm to convert
exposure questionnaire information objec-
tively for use in biokinetic modeling. Each
occupational activity that involved risk of Pb
exposure was assigned the probability and
intensity scale values of the activity (low,
medium, and high), converted to 1, 2, or 3,
respectively. The daily Pb input to the model
from a particular activity was then determined
using the following formula:
Daily Pb input =
P × intensity × (activity hours)
× 10 µg Pb/day,
40
where P is the probability of Pb exposure
because of job classiﬁcation; “intensity” is the
intensity of exposure; and “activity hours” is
the number of hours devoted to the activity
per 40-hr work week. The value of 10 µg
Pb/day was derived from the assumption that
an individual working 40 hr/week in a “high
probability/high intensity” exposure activity
should have a blood Pb level just above
40 µg/dL (Patterson 1980). A calculation of
3 × 3 × (40/40) × 10 = 90 µg/dL gave sufﬁ-
cient daily Pb input above the baseline to
result in blood Pb levels of 42 µg/dL during
this activity. We then calculated the total life-
time exposure for each individual by adding
the Pb exposure questionnaire-derived values
for each occupation plus the baseline Pb
input at that subject’s age at enrollment.
Next, we incorporated age-dependent changes
in bone remodeling rates and skeletal mass
above the age of 60 years and scaled the bio-
kinetic model to an individual subject’s body
weight, rather than to the commonly used
70-kg reference man (ICRP 1995).
We adjusted the intensity of Pb exposure
(micrograms of Pb per day) in the model for
the current blood Pb level, and for trabecular
(calcaneus) and cortical (tibia) bone Pb con-
centration to minimize the model fit error
using the formula
This calculation weights the model ﬁtting to
the K-XRF measurement of the tibia (cortical
bone) because of the longer half-life of Pb in
cortical bone and because the error of K-XRF
measurement is smaller than for trabecular
bone. The use of this equation provides an
objective description of the model’s ﬁt to lim-
ited data. Input K-XRF estimates of bone Pb
ranged from 4.5 to 54.4 µg/g (micrograms of
Pb per gram of bone) with a mean ± SD of
12.5 ± 7.8 µg/g for tibial measurements and
from 9.3 to 64.4 µg/g with a mean of 20.5
± 10.2 µg/g for calcaneal measurements. The
resulting model ﬁt error ranged from –37.5 to
18.5 µg/g and produced a mean error of –4.0
± 6.7 µg/g.
Statistical methods. To assess the distribu-
tion of exposures among case and control par-
ticipants, we used chi-square analysis. To
assess the relationship of Pb exposure to the
presence of PD we used multiple logistic
regression techniques, using the presence or
absence of PD as the dependent variable.
Odds ratios (ORs) and their associated 95%
conﬁdence intervals (CIs) were calculated. For
all models a p-value < 0.05 was considered
statistically significant. For Pb exposure, we
calculated the whole-body lifetime Pb expo-
sure as described above and categorized the
participants into four quartiles based on the
mean exposure per year for the control group:
first quartile [0–40.04 µg/g (micrograms 
Pb storage per gram of bone)], second
(40.05–57.43 µg/g), third (57.44–80.80 µg/g),
and fourth (≥ 80.81 µg/g). Logistic regression
analysis was run with three indicator variables
and the ﬁrst quartile of exposure serving as the
reference group. The range of whole-body life-
time Pb exposure measurements was skewed
by several large exposure values, making the
data difﬁcult to model as a continuous variable.
A log-transform of the data modeled well, and
these results are also included below.
Results of the K-XRF measurements were
also examined via logistic regression using
either tibia or calcaneus Pb exposure as the
independent variable to be associated with PD.
Tibia bone Pb exposure was categorized into
quartiles based on the exposure of the control
group as follows: first (0–5.91 µg/g), second
(5.92–10.40 µg/g), third (10.41–15.50 µg/g),
and fourth (≥ 15.51 µg/g). Finally, calcaneus
bone Pb exposure was categorized into quar-
tiles based on the exposure of the control
group as follows: ﬁrst (0–11.70 µg/g), second
(11.71–19.07 µg/g), third (19.08–25.28 µg/g),
and fourth (≥ 25.29 µg/g).
In adjusted logistic regression models, we
included the matching covariates of age, sex,
and race. Although we modeled age as a contin-
uous variable, sex and race were both included
as dichotomous variables of male/female and
white/nonwhite, respectively. Because smoking
history, coffee consumption, and alcohol con-
sumption have been reported on extensively as
effect modiﬁers in determining PD risk, we also
included these factors in adjusted models. We
calculated pack-years of smoking history (i.e.,
packs of cigarettes per day multiplied by years
smoked), and categorized smokers into three
groups: none (0 pack-years), mild to moderate
(> 0 to 30 pack-years), and heavy (> 30 pack-
years). The analysis thus ran two indicator
variables, with nonsmokers serving as the ref-
erence group. We defined “coffee consump-
tion history” as the number of coffee-years,
where a “coffee-year” was deﬁned as one cup
of coffee per day for 1 year. We categorized
coffee drinkers, using the median coffee con-
sumption for the control group, as low
(> 0–112 coffee-years) and high (> 112 coffee-
years). Two indicator variables were used in the
logistic regression analysis, and “no coffee con-
sumption” served as the reference group. For
alcoholic consumption, we deﬁned a “drink-
year” as the intake of one “drink” of alcohol
per day for 1 year. We defined a “drink” of
alcohol as follows: liquor (30 mL), one can of
beer (360 mL), or one glass of wine (120 mL).
We classified participants as nondrinkers
(0 drink-years), mild to moderate drinkers
(> 0–10 drink-years), or heavy drinkers
(> 10 drink-years). Two indicator variables
were used in the logistic regression analysis and
nondrinkers served as the reference group.
Model ﬁt error = 
[(K-XRFtibia – modelcortical bone) × 2 
+ (K-XRFcalcaneus – modeltrabecular bone)] ÷ 3.
Coon et al.
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We enrolled 535 nondemented men and
women ≥ 50 years of age. The average age of
participants in the study was 69.9 ± 8.2 years
and did not differ from nonparticipants (69.7
± 9.1; p = 0.69, Student’s t-test). Also, race did
not differ significantly between participants
(85.8% white) and nonparticipants (83.2%
white; p = 0.19, Mantel-Haenszel chi-square).
Sex, however, did differ signiﬁcantly between
participants (56.6% male) and nonparticipants
(45.7% male; p = 0.001, Mantel-Haenszel chi-
square). This difference resulted from the com-
bination of both a higher incidence of PD
within males and our inability to recruit
healthy males as effectively as healthy females
for participation.
Of the 535 participants, 121 had a veriﬁed
idiopathic diagnosis of PD, and 414 were
healthy age-, sex-, and race-, frequency-
matched controls (Table 1). This included 303
(56.6%) males and 232 (43.4%) females, 460
(86.0%) whites and 75 (14.0%) nonwhites.
Even with a recruitment protocol designed for
frequency matching, we observed a statistical
difference for age and race. Individuals
≥ 70 years of age (p = 0.001) and whites (p =
0.038) were underrepresented among healthy
controls compared with PD cases. Cases had
an average age of 72.3 years (median 73.1
years) and controls had an average age of
69.7 years (median 70.0 years). Although
males were also somewhat underrepresented
among healthy controls, the difference from
cases did not reach statistical signiﬁcance. To
account for the difﬁculty in balancing recruit-
ment among these groups, the final logistic
regression models included adjustment for
these variables. Distributions of the covariates
for smoking history, coffee consumption, and
alcohol consumption are shown in Table 1.
Patients with PD were more likely to be non-
smokers or to be lighter smokers than healthy
controls (p = 0.002). Controls were nearly
twice as likely to be heavy smokers (> 30 pack-
year history). PD patients were also less likely
to be coffee drinkers than controls (p = 0.007).
No difference in alcoholic consumption was
observed between patients with PD and
healthy control volunteers.
Participants were categorized into quar-
tiles of exposures individually for categories of
whole-body lifetime Pb exposure, K-XRF cal-
caneal bone Pb measurement, and K-XRF
tibial bone Pb measurement, as described in
“Materials and Methods.” Among patients
with PD, whole-body Pb concentrations were
lowest in the ﬁrst quartile (14.9%) and high-
est in the fourth quartile (32.2%), yielding a
positive indication for an association between
Pb exposure and PD (p-trend = 0.036).
Delegation of tibial K-XRF measurements into
quartiles also reveals a signiﬁcant trend from
the ﬁrst to fourth quartile (p-trend = 0.012). A
statistically signiﬁcant trend is not seen, how-
ever, when applied to quartiles of calcaneal
K-XRF measurements (p-trend = 0.275).
Results from logistic regression modeling
of quartiles of whole-body lifetime Pb expo-
sure showed a statistically signiﬁcant elevation
of risk of PD for those in the fourth (highest
exposure) quartile compared with those in the
ﬁrst (lowest exposure) quartile (Table 2). The
estimated OR, 95% CI, and p-value indicate
an elevated risk of PD for those in the fourth
quartile, adjusting for age, sex, race, smoking,
and coffee and alcohol consumption [OR =
2.27 (95% CI, 1.13–4.55); p = 0.021].
Individuals who experienced the highest quar-
tile of exposure were twice as likely to have PD
than those in the lowest quartile of exposure.
The risk estimates for tibial and calcaneal
K-XRF measurements of bone Pb concentra-
tions alone (without incorporation of duration
and intensity of occupational exposure data or
blood Pb levels) were elevated in increasing
quartiles of exposure, but these data did not
reach statistical significance. In the adjusted
lifetime Pb exposure model, moderate [OR =
0.58 (95% CI, 0.35–0.95); p = 0.029] and
heavy [OR = 0.33 (95% CI, 0.17–0.65);
p = 0.001] levels of smoking were associated
with reduced risks of PD. Also, mild-to-mod-
erate [OR = 0.41 (95% CI, 0.22–0.75);
p = 0.004] and heavy [OR = 0.36 (95% CI,
0.19– 0.68); p = 0.002] coffee drinkers dis-
played a reduced risk of PD as well. Neither
mild-to-moderate nor heavy alcohol consump-
tion was signiﬁcantly associated with PD risk.
We then analyzed the log transformation
of the continuous lifetime Pb exposure data
by logistic regression. Adjusted, whole-body
lifetime Pb remained signiﬁcant [OR = 1.74
(95% CI, 1.10–2.75); p = 0.018], whereas
K-XRF measurements of tibia [OR = 1.47
(95% CI, 0.99–2.20); p = 0.059] and cal-
caneal [OR = 1.53 (95% CI, 0.93–2.54);
p = 0.097] did not reach statistical signifi-
cance. Stratiﬁed analysis pointed to a stronger
association between lifetime Pb exposure and
PD risk for those older than [OR = 2.17
(95% CI, 1.16–4.06); p = 0.015] compared
with those younger than [OR = 1.30 (95%
CI, 0.62–2.70); p = 0.49] the median age
(70.7 years), but testing for an interaction did
not show a statistically significant difference
between the odds ratios (p = 0.24). Similarly,
stratified analysis by sex suggested that the
association of lifetime Pb exposure to PD risk
was higher in females [OR = 2.23 (95% CI,
1.05–4.76); p = 0.038] than in males [OR =
1.53 (95% CI, 0.83–2.80); p = 0.17], but an
interaction test showed that this difference
was not statistically signiﬁcant (p = 0.50).
Independent of PD diagnosis, age, sex,
smoking, coffee, and alcohol were associated
with whole-body lifetime Pb exposure (data
not shown) but race was not. Even so, the esti-
mate of PD risk changed very little before and
after adjustment for these covariates. The
logistic model for whole-body lifetime Pb
exposure had 99% and 98% power to detect a
difference in the unadjusted and adjusted
Occupational Pb exposure and Parkinson’s disease
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Table 1. Distribution of matched variables and
potential confounders for cases (n = 121) and con-
trols (n = 414).
Matching Cases Controls
variable [no. (%)] [no. (%)] p-Valuea
Age (years)
50–59 9 (7.4) 60 (14.5) 0.001*
60–69 27 (22.3) 147 (35.5)
70–79 63 (52.1) 166 (40.1)
≥ 80 22 (18.2) 41 (9.9)
Sex 
Male 76 (62.8) 227 (54.8) 0.119
Female 45 (37.2) 187 (45.2)
Race
White 111 (91.7) 349 (84.3) 0.038*
Nonwhite 10 (8.3) 65 (15.7)
Smoking
None 70 (57.9) 166 (40.1) 0.002*
Mild to moderate 36 (29.8) 158 (38.2)
Heavy 15 (12.4) 90 (21.7)
Coffee
None 30 (24.8) 53 (13.0) 0.007*
Mild to moderate 46 (38.0) 180 (44.1)
Heavy 45 (37.2) 175 (42.9)
Alcohol
None 20 (16.5) 53 (13.0) 0.544
Mild to moderate 45 (37.2) 168 (41.1)
Heavy 56 (46.3) 188 (46.0)
aChi-square. *Statistically signiﬁcant.
Table 2. Risk of PD by whole-body lifetime Pb exposure and K-XRF point measurements of lead exposure.
Unadjusted Adjusteda
Variable OR (95% CI) p-Value OR (95% CI) p-Value
Whole body
Second quartile 1.87 (0.99–3.52) 0.052 1.90 (0.97–3.71) 0.060
Third quartile 1.67 (0.87–3.18) 0.121 1.71 (0.86–3.41) 0.125
Fourth quartile 2.15 (1.15–4.00) 0.016* 2.27 (1.13–4.55) 0.021*
Tibia
Second quartile 0.90 (0.47–1.73) 0.762 0.87 (0.43–1.75) 0.691
Third quartile 1.52 (0.84–2.75) 0.165 1.33 (0.70–2.52) 0.387
Fourth quartile 1.81 (1.02–3.22) 0.044* 1.62 (0.83–3.17) 0.160
Calcaneus
Second quartile 1.67 (0.92–3.02) 0.092 1.71 (0.91–3.20) 0.094
Third quartile 1.18 (0.63–2.22) 0.604 1.12 (0.57–2.22) 0.737
Fourth quartile 1.62 (0.89–2.94) 0.113 1.50 (0.75–3.00) 0.253
aAdjusted for age, sex, race, smoking, and coffee and alcohol consumption. *Statistically signiﬁcant.Coon et al.
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models, respectively. The logistic model for
tibial K-XRF measurement of Pb exposure
had 92% and 72% power to detect a differ-
ence in the unadjusted and adjusted models,
respectively. The logistic model for tibial
K-XRF measurement of Pb exposure had 57%
and 79% power to detect a difference in the
unadjusted and adjusted models, respectively.
Discussion
Occupational exposure to heavy metals is asso-
ciated with the risk of PD (Gorell et al. 1997).
Assessment of blood Pb concentration as a
proxy for chronic or distant past exposure is
inconclusive because of the body’s ability to
purge metals quickly from the blood stream.
We used K-XRF technology to improve the
assessment of chronic Pb exposure by measur-
ing long-term Pb stores in the body. The use of
K-XRF represents an advancement in method-
ology beyond our earlier work, which subjec-
tively assessed occupational exposure to Pb
by an experienced industrial hygienist (Todd
and Chettle 1994; Uversky et al. 2001).
Additionally, we employed PBPK modeling,
which combined the bone Pb concentration
with occupational history and blood Pb con-
centration to estimate whole-body lifetime Pb
burden. Our ﬁndings show that higher lifetime
exposure to Pb is associated with risk of PD
and conﬁrm previous ﬁndings that prolonged
occupational exposure to Pb increases the risk
of PD by more than 2-fold (Gorell et al.
1997). This study agrees with the ﬁndings of
several other epidemiologic studies and further
supports an association between PD and expo-
sure to heavy metals (Aquilonius and Hartvig
1986; Rybicki et al. 1993; Tanner et al. 1989).
Recall bias is a primary source for error in
the study of occupational exposure to heavy
metals. This can manifest as either omission of
exposure or exaggeration of duration and/or
intensity of exposure. In an effort to reduce
recall bias, we supplemented the participant’s
self-report with the experience of the industrial
hygienist to determine if Pb was used in a spe-
ciﬁc occupation. Also, by focusing primarily on
occupational exposures—verifiable by the
industrial hygienist—rather than environ-
mental and recreational exposure, we further
reduced the likelihood of spurious findings.
Another limitation of the present study
involves the failure to accurately match cases
and controls on age and sex. Individuals
≥ 70 years of age were underrepresented in
the control group compared to the cases.
Adjustment for age in the logistic model that
tested for the association of Pb exposure on PD
risk did appreciably alter the effect size or the
signiﬁcance level. The results of the stratiﬁed
analysis point to age as being an effect modiﬁer
for the association of Pb exposure to PD risk,
but not the source of the effect itself. Similarly,
males were underrepresented in the control
group compared to cases. Here also, the adjust-
ment for sex did not signiﬁcantly change the
effect size or signiﬁcance level of the association
between Pb exposure and risk of PD. The
stratiﬁed analysis showed elevated ORs in both
males and females that, while not signiﬁcantly
different, were stronger in females. More par-
ticipants than nonparticipants were male, and
this may have resulted in a further source of
error. Because the association between Pb
exposure and PD was stronger in females, it
might be expected that the overall association
in the general population would be stronger
than that reported above.
This study supports the hypothesis that Pb
plays a role in the etiology of PD in exposed
individuals. Although the biochemical mecha-
nism of Pb neurotoxicity is not completely
understood, a growing body of evidence sug-
gests that metal cations of Pb, iron, and alu-
minum stimulate free radical formation,
which results in neurodegeneration via peroxi-
dative damage to the cell wall. Sandhir et al.
(1994) observed that increasing Pb concentra-
tion in rat brain produces heightened levels of
lipid peroxidation and decreased activity of
neuroprotective antioxidant enzymes and
acetylcholinesterase. The authors suggested
that lipid peroxidation eventually can lead to
neuronal cell death through deterioration of
the cell membrane. Uversky et al. (2001),
using in vitro models of human brain cells,
found that increasing levels of heavy metal
cations stimulate the conformational changes
that can lead to fibrillation of recombinant
α-synuclein. The authors argued that the
aggregation and fibrillation of α-synuclein
provoked by the presence of heavy metal
cations could directly cause the intracellular
protein inclusions that are observed in the
substantia nigra of PD patients. Quinlan et al.
(1988) observed that although Pb ions alone
did not induce peroxidation, they did acceler-
ate the rate of peroxidation caused by iron
ions. The present study provides additional
objective evidence to support the hypothesis
that long-term exposure to heavy metals, such
as Pb, contributes to the accumulation of per-
oxidative damage and neurodegenerative cell
death that is observed in PD.
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